{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:24Z","timestamp":1787027904540,"version":"build-2736575974"},"reference-count":29,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CADTH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Niraparib was recently funded in Canada for the maintenance treatment of ovarian cancer following platinum-based chemotherapy. However, the drug\u2019s safety profile in the real world remains uncertain. We conducted a cohort study to describe the patient population using niraparib and the proportion that experienced adverse events between June 2019 and December 2022 in four Canadian provinces (Ontario, Alberta, British Columbia [BC], and Quebec). We used administrative data and electronic medical records from Ontario Health, Alberta Health Services, and BC Cancer, and registry data from Exactis Innovation. We summarized baseline characteristics using descriptive statistics and reported safety outcomes using cumulative incidence. We identified 514 patients receiving niraparib. Mean age was 67 years and most were initiated on a daily dose of 100 or 200 mg\/day. Grade 3\/4 anemia, neutropenia, and thrombocytopenia occurred in 11\u201316% of the cohort. In Ontario, the three-month cumulative incidence of grade 3\/4 thrombocytopenia was 11.6% (95% CI, 8.3\u201315.4%), neutropenia was 7.1% (95% CI, 4.6\u201310.4%), and anemia was 11.3% (95% CI, 8.0\u201315.2%). Cumulative incidences in the remaining provinces were similar. Initial daily dose and proportions of hematological adverse events were low in the real world and may be related to cautious prescribing and close monitoring by clinicians.<\/jats:p>","DOI":"10.3390\/curroncol31060264","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T12:27:33Z","timestamp":1718972853000},"page":"3591-3602","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Safety of Niraparib for Maintenance Treatment of Ovarian Cancer in Canada"],"prefix":"10.3390","volume":"31","author":[{"given":"Qi","family":"Guan","sequence":"first","affiliation":[{"name":"Ontario Health, Toronto, ON M5G 2L3, Canada"},{"name":"Canadian Cancer Real-World Evaluation Platform, Toronto, ON M5G 2L3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suriya J.","family":"Aktar","sequence":"additional","affiliation":[{"name":"Ontario Health, Toronto, ON M5G 2L3, Canada"},{"name":"Canadian Cancer Real-World Evaluation Platform, Toronto, ON M5G 2L3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0159-582X","authenticated-orcid":false,"given":"Reka E.","family":"Pataky","sequence":"additional","affiliation":[{"name":"Canadian Cancer Real-World Evaluation Platform, Toronto, ON M5G 2L3, Canada"},{"name":"Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada"},{"name":"BC Cancer, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariet Mathew","family":"Stephen","sequence":"additional","affiliation":[{"name":"Canadian Cancer Real-World Evaluation Platform, Toronto, ON M5G 2L3, Canada"},{"name":"Oncology Outcomes, Calgary, AB T2N 1N4, Canada"},{"name":"Alberta Health Services, Edmonton, AB T5J 3E4, Canada"},{"name":"Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Marques","sequence":"additional","affiliation":[{"name":"Exactis Innovation, Montreal, QC H3T 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Gambaro","sequence":"additional","affiliation":[{"name":"Exactis Innovation, Montreal, QC H3T 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahina","family":"Rachedi","sequence":"additional","affiliation":[{"name":"Exactis Innovation, Montreal, QC H3T 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Forster","sequence":"additional","affiliation":[{"name":"Ontario Health, Toronto, ON M5G 2L3, Canada"},{"name":"Canadian Cancer Real-World Evaluation Platform, Toronto, ON M5G 2L3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samara","family":"Strub","sequence":"additional","affiliation":[{"name":"Ontario Health, Toronto, ON M5G 2L3, Canada"},{"name":"Canadian Cancer Real-World Evaluation Platform, Toronto, ON M5G 2L3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Stock","sequence":"additional","affiliation":[{"name":"CADTH, Ottawa, ON K1S 5S8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"de L\u00e9s\u00e9leuc","sequence":"additional","affiliation":[{"name":"CADTH, Ottawa, ON K1S 5S8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winson Y.","family":"Cheung","sequence":"additional","affiliation":[{"name":"Canadian Cancer Real-World Evaluation Platform, Toronto, ON M5G 2L3, Canada"},{"name":"Oncology Outcomes, Calgary, AB T2N 1N4, Canada"},{"name":"Alberta Health Services, Edmonton, AB T5J 3E4, Canada"},{"name":"Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8243-8721","authenticated-orcid":false,"given":"Stuart","family":"Peacock","sequence":"additional","affiliation":[{"name":"Canadian Cancer Real-World Evaluation Platform, Toronto, ON M5G 2L3, Canada"},{"name":"BC Cancer, Vancouver, BC V5Z 4E6, Canada"},{"name":"Faculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie","family":"Farrer","sequence":"additional","affiliation":[{"name":"Canadian Cancer Real-World Evaluation Platform, Toronto, ON M5G 2L3, Canada"},{"name":"Oncology Outcomes, Calgary, AB T2N 1N4, Canada"},{"name":"Alberta Health Services, Edmonton, AB T5J 3E4, Canada"},{"name":"Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8635-6889","authenticated-orcid":false,"given":"Scott","family":"Gavura","sequence":"additional","affiliation":[{"name":"Ontario Health, Toronto, ON M5G 2L3, Canada"},{"name":"Canadian Cancer Real-World Evaluation Platform, Toronto, ON M5G 2L3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-6129","authenticated-orcid":false,"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[{"name":"Canadian Cancer Real-World Evaluation Platform, Toronto, ON M5G 2L3, Canada"},{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 1A1, Canada"},{"name":"Women\u2019s College Hospital, Toronto, ON M5S 1B2, Canada"},{"name":"ICES, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Grant","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelvin K. W.","family":"Chan","sequence":"additional","affiliation":[{"name":"Ontario Health, Toronto, ON M5G 2L3, Canada"},{"name":"Canadian Cancer Real-World Evaluation Platform, Toronto, ON M5G 2L3, Canada"},{"name":"Canadian Centre for Applied Research in Cancer Control, Toronto, ON M5G 2L3, Canada"},{"name":"ICES, Toronto, ON M4N 3M5, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada"},{"name":"Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"ref_1","unstructured":"(2023, December 01). Canadian Cancer Society Cancer Statistics at a Glance. Available online: https:\/\/cancer.ca\/en\/research\/cancer-statistics\/cancer-statistics-at-a-glance?gad_source=1&gclid=EAIaIQobChMI0_n-i-f4ggMVtNDCBB10LQ6uEAAYASAAEgKr0_D_BwE."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.3390\/curroncol29060348","article-title":"A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers","volume":"29","author":"Tinker","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_3","unstructured":"(2023, July 23). Canadian Cancer Society Survival Statistics for Ovarian Cancer. Available online: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/ovarian\/prognosis-and-survival\/survival-statistics."},{"key":"ref_4","unstructured":"Canadian Cancer Society (2023, July 23). Ovarian Cancer. Available online: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/ovarian."},{"key":"ref_5","unstructured":"Ontario Health (2023). Homologous Recombination Deficiency Testing to Inform Patient Decisions about Niraparib Maintenance Therapy for High-Grade Serous or Endometrioid Epithelial Ovarian Cancer: Recommendation, Ontario Health."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Pothuri","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib Maintenance Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Cancer Using an Individualized Starting Dose (NORA): A Randomized, Double-Blind, Placebo-Controlled Phase III Trial\u2606","volume":"32","author":"Wu","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1136\/ijgc-2023-004484","article-title":"Real-World Data on Niraparib Maintenance Treatment in Patients with Non-gBRCA Mutated Platinum-Sensitive Recurrent Ovarian Cancer","volume":"33","author":"Vilming","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s11523-023-00999-x","article-title":"Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China","volume":"18","author":"Zhao","year":"2023","journal-title":"Targ. Oncol."},{"key":"ref_11","unstructured":"GlaxoSmithKline (2023, July 23). ZEJULA\u2014A New Maintenance Treatment Option for Canadians Living with Ovarian Cancer\u2014Now Available in Canada. Available online: https:\/\/ca.gsk.com\/en-ca\/media\/press-releases\/zejula-a-new-maintenance-treatment-option-for-canadians-living-with-ovarian-cancer-now-available-in-canada\/."},{"key":"ref_12","unstructured":"GlaxoSmithKline (2023, July 23). ZEJULA Is Approved in Canada for First-Line Maintenance Treatment of Women with Advanced Ovarian Cancer. Available online: https:\/\/www.newswire.ca\/news-releases\/zejula-is-approved-in-canada-for-first-line-maintenance-treatment-of-women-with-advanced-ovarian-cancer-849289412.html."},{"key":"ref_13","unstructured":"BC Cancer (2023, July 23). Systemic Therapy Update. Available online: http:\/\/www.bccancer.bc.ca\/health-professionals\/clinical-resources\/systemic-therapy\/systemic-therapy-update."},{"key":"ref_14","unstructured":"Ontario Ministry of Health (2023, July 23). Exceptional Access Program Reimbursement Criteria for Frequently Requested Drugs. Available online: https:\/\/files.ontario.ca\/moh-frequently-requested-drugs.pdf."},{"key":"ref_15","unstructured":"Alberta Health Services (2024, April 16). Outpatient Cancer Drug Benefit Program. Available online: https:\/\/www.albertahealthservices.ca\/services\/page2328.aspx."},{"key":"ref_16","unstructured":"Regie de L\u2019assurance Maladie du Quebec (2023, July 23). Liste Des Medicaments\u201429 Septembre 2021, Available online: https:\/\/www.ramq.gouv.qc.ca\/fr\/media\/12091."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jama.2023.4855","article-title":"Randomized Trials vs. Real-World Evidence: How Can Both Inform Decision-Making?","volume":"329","author":"Sheldrick","year":"2023","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.3346\/jkms.2018.33.e213","article-title":"Real-World Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records","volume":"33","author":"Kim","year":"2018","journal-title":"J. Korean Med. Sci."},{"key":"ref_19","unstructured":"(2024, April 16). CoLab Mainpage. Available online: https:\/\/colab.cadth.ca\/."},{"key":"ref_20","unstructured":"(2024, April 16). CCRE Mainpage. Available online: https:\/\/ccreplatform.com\/."},{"key":"ref_21","unstructured":"(2024, April 16). Exactis Innovation Mainpage. Available online: https:\/\/www.exactis.ca\/."},{"key":"ref_22","unstructured":"ClinicalTrials.gov (2023, July 23). Personalize My Treatment (PMT) Registry (PMT), Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT02355171?cond=NCT02355171&rank=1."},{"key":"ref_23","unstructured":"National Cancer Institute (2023, July 23). Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1002\/sim.9023","article-title":"Fine-Gray Subdistribution Hazard Models to Simultaneously Estimate the Absolute Risk of Different Event Types: Cumulative Total Failure Probability May Exceed 1","volume":"40","author":"Austin","year":"2021","journal-title":"Stat. Med."},{"key":"ref_25","unstructured":"Allison, P.D. (2010). Survival Analysis Using SAS: A Practical Guide, SAS Press. [2nd ed.]."},{"key":"ref_26","unstructured":"Guan, Q., Aktar, S., Pataky, R., Stephen, M.M., Marques, M., Gambaro, K., Forster, K., Strub, S., Cheung, W.Y., and Peacock, S. (2024). The Safety of Niraparib in Ovarian Cancer, Canadian Cancer Real-World Evaluation Platform."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jjco\/hyad125","article-title":"Efficacy and Safety of Olaparib, Olaparib plus Bevacizumab and Niraparib Maintenance Treatment in Japanese Patients with Platinum-Sensitive Advanced Ovarian Cancer","volume":"54","author":"Nakamura","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cac2.12418","article-title":"Real-world Outcomes of Niraparib Treatment in Patients with Ovarian Cancer: A Multicenter Non-interventional Study in China","volume":"43","author":"Li","year":"2023","journal-title":"Cancer Commun."},{"key":"ref_29","unstructured":"GlaxoSmithKline (2024, April 16). Product Monograph Including Patient Medication Information: Zejula. Available online: https:\/\/ca.gsk.com\/media\/6229\/zejula_pm_en.pdf."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/6\/264\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:01:13Z","timestamp":1760108473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/6\/264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["curroncol31060264"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31060264","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]}}}